Impact of Donor Diabetes Severity on 1-Year Outcomes After Descemet Membrane Endothelial Keratoplasty: Insights from the Diabetes Endothelial Keratoplasty Study

Impact of Donor Diabetes Severity on 1-Year Outcomes After Descemet Membrane Endothelial Keratoplasty: Insights from the Diabetes Endothelial Keratoplasty Study

A thorough secondary analysis of a randomized clinical trial reveals no significant association between cornea donor diabetes severity and graft success, endothelial cell loss, or morphometric parameters at 1 year post-DMEK, supporting the use of diabetic donor corneas without additional preoperative risk stratification.
Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: An Emerging Therapeutic Strategy

Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: An Emerging Therapeutic Strategy

This review synthesizes evidence on disitamab vedotin combined with tislelizumab showing promising efficacy and safety in treating transurethrally unresectable ERBB2-positive very high-risk NMIBC, filling a crucial therapeutic gap for patients ineligible for cystectomy.